Cleomiscosin C has antioxidant activity, it protects against the oxidative modification of apoB-100 induced by either Cu2+ or HOCl ( IC50s of 23.6 and 3.9 microM, respectively), suggests that it could be beneficial in preventing LDL oxidation in atheroscl
Stachybotramide preferentially stimulate the plasma cholesteryl ester transfer protein (CETP)-mediated transfer of cholesteryl esters (CE) from high density lipoprotein (HDL) to both very low density lipoprotein (VLDL) and low density lipoprotein (LDL).
Trichosanatine and squamosamide, as potential candidates as lead compounds for further study in drug development process with the PP2A- α protein. Trichosanatine can alleviate oxidized low-density lipoprotein induced endothelial cells injury via inhibiting the LOX-1 p38 MAPK pathway.
Alpinumisoflavone has atheroprotective effects, may result from their ability to upregulate mechanisms promoting HDL-cholesterol and bile acid formation, it is endowed with estrogenic properties accounting, at least in part, for E. lysistemon effects. Alp
Ligupurpuroside A has antioxidant,and hypolipidemic effects, it can significantly inhibit lipid accumulation in HepG2 cell at the concentration of 50 μMol L.
Tanshindiol C protects macrophages from oxLDL induced foam cell formation via activation of Prdx1 ABCA1 signaling and that Prdx1 may be a novel target for therapeutic intervention of atherosclerosis.It possesses a unique anti-cancer activity whose mechani